FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
Executive Summary
MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine
You may also be interested in...
FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says
MedImmune is considering reducing the price for the intranasal flu vaccine FluMist to $20-$25 per dose for the 2004-2005 season, CEO David Mott indicated during a first quarter conference call April 21
FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says
MedImmune is considering reducing the price for the intranasal flu vaccine FluMist to $20-$25 per dose for the 2004-2005 season, CEO David Mott indicated during a first quarter conference call April 21
MedImmune To Continue FluMist Development; Wyeth Remains Undecided
MedImmune is confident it can successfully develop FluMist on its own should Wyeth decide to back out of the companies' partnership for the intranasal flu vaccine